Eli Lilly - 50 Year Stock Price History | LLY

Historical daily share price chart and data for Eli Lilly since 1972 adjusted for splits. The latest closing stock price for Eli Lilly as of August 18, 2022 is 316.72.
  • The all-time high Eli Lilly stock closing price was 330.55 on July 15, 2022.
  • The Eli Lilly 52-week high stock price is 335.33, which is 5.9% above the current share price.
  • The Eli Lilly 52-week low stock price is 220.20, which is 30.5% below the current share price.
  • The average Eli Lilly stock price for the last 52 weeks is 274.07.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Eli Lilly Historical Annual Stock Price Data
Year Average Stock Price Year Open Year High Year Low Year Close Annual % Change
2022 286.1565 268.8386 330.5485 233.1623 316.7200 15.90%
2021 220.8520 161.2968 276.0708 160.1468 273.2808 66.08%
2020 143.6402 126.3001 168.2457 114.3218 164.5520 31.06%
2019 110.5180 107.9368 126.5102 101.4290 125.5549 15.48%
2018 87.0774 77.6158 111.4695 68.0192 108.7260 40.45%
2017 74.4313 66.6353 80.5580 66.6175 77.4141 17.83%
2016 67.3779 72.0926 73.7122 58.9267 65.6974 -10.37%
2015 67.7557 59.3756 77.7921 58.3916 73.3018 25.37%
2014 51.5021 41.6155 61.7231 41.6155 58.4687 39.75%
2013 42.4387 39.1636 46.5635 38.7136 41.8370 7.24%
2012 33.7599 31.5764 42.1272 29.4427 39.0133 24.27%
2011 27.1426 25.0578 31.5386 24.4187 31.3951 25.15%
2010 24.5139 24.2629 26.8723 22.4702 25.0864 3.71%
2009 22.6346 25.9923 25.9923 17.8343 24.1884 -6.25%
2008 28.4820 32.2383 35.0787 19.1627 25.8001 -21.23%
2007 33.5362 31.0905 36.3174 30.1156 32.7536 5.65%
2006 32.3087 33.1324 34.4062 29.5579 31.0013 -5.16%
2005 31.3467 31.6038 34.3660 28.5316 32.6877 2.52%
2004 36.5863 39.1720 42.1315 28.1597 31.8847 -17.55%
2003 34.5781 35.6540 40.6291 29.0687 38.6716 13.14%
2002 34.5607 41.4370 42.7665 25.6425 34.1792 -17.56%
2001 41.8072 47.6425 47.6425 37.9286 41.4581 -14.44%
2000 40.7314 33.6593 56.1345 28.0990 48.4547 41.92%
1999 38.5984 43.6098 49.5409 31.4795 34.1419 -24.25%
1998 36.0179 34.5703 46.0844 29.2981 45.0702 29.08%
1997 26.1729 17.8607 35.0718 17.8607 34.9163 94.15%
1996 15.3843 13.3490 19.5236 11.9317 17.9839 32.64%
1995 9.5365 7.6005 13.6190 7.3244 13.5588 77.39%
1994 6.4358 6.6120 7.6436 5.3464 7.6436 15.60%
1993 5.6227 6.5193 6.7501 4.8050 6.6120 2.47%
1992 7.1479 8.7329 8.9634 6.1982 6.4524 -24.89%
1991 7.8867 7.3295 8.7329 6.9517 8.5909 16.41%
1990 7.1398 6.7363 8.9414 5.8551 7.3798 9.95%
1989 5.5144 4.0942 6.7118 4.0942 6.7118 64.17%
1988 3.9141 3.7055 4.3523 3.2990 4.0884 12.81%
1987 4.0642 3.4272 4.8291 2.8618 3.6242 5.75%
1986 3.2220 2.5329 3.8081 2.3483 3.4272 33.18%
1985 1.9575 1.4974 2.5733 1.4944 2.5733 68.94%
1984 1.4053 1.3732 1.5435 1.2463 1.5232 14.03%
1983 1.4459 1.3243 1.5781 1.3097 1.3358 0.66%
1982 1.3133 1.2867 1.5001 1.0732 1.3270 2.68%
1981 1.3461 1.4540 1.5751 1.0759 1.2924 -11.98%
1980 1.2299 1.3386 1.4683 1.0644 1.4683 6.71%
1979 1.2764 1.1078 1.4655 1.0990 1.3760 24.86%
1978 1.0385 0.8712 1.2405 0.8482 1.1020 26.06%
1977 0.8955 1.0875 1.0875 0.7588 0.8742 -20.45%
1976 1.1904 1.1798 1.3847 1.0067 1.0990 -7.75%
1975 1.5176 1.5491 1.8260 1.1743 1.1913 -24.09%
1974 1.6005 1.6935 1.8953 1.2982 1.5694 -8.11%
1973 1.8835 1.8260 2.1145 1.6183 1.7079 -7.06%
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $301.034B $28.318B
Eli Lilly and Company, one of the world's largest pharmaceutical companies, boasts a diversified product profile including a solid lineup of new successful drugs. It also has a dependable pipeline as it navigates through challenges like patent expirations of several drugs and rising pricing pressure on its U.S. diabetes franchise. Its pharmaceutical product categories are neuroscience, diabetes, oncology, immunology and others. Over the past few years, Lilly has been actively seeking acquisitions and in-licensing deals to boost its product portfolio and pipeline. The purchase of ImClone Systems brought with it cancer compound, Erbitux. The acquisition of ICOS Corporation gave Lilly full control over erectile dysfunction drug, Cialis. Its other acquisitions include Hypnion, Inc., CoLucid Pharmaceuticals added Reyvow for acute migraine, Loxo Oncology and Dermira. Lilly has collaboration agreements with several companies including Incyte, Boehringer Ingelheim and Innovent Biologics among others.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $440.598B 16.77
Pfizer (PFE) United States $276.521B 8.10
AbbVie (ABBV) United States $250.080B 10.63
Novo Nordisk (NVO) Denmark $237.182B 31.29
Merck (MRK) United States $230.630B 12.04
Novartis AG (NVS) Switzerland $188.558B 13.90